NEWS

WIRES

OTHER

Research and Markets: Thought Leader Insight & Analysis Report - Ovarian Cancer Q1 2010 Identifies Strengths and Weaknesses for Lead Compounds in Development for Ovarian Cancer

Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15,000 women die each year in the US from ovarian cancer. While the 5-year survival for non-metastatic disease is 75%, only 20% of metastatic patients live this long. Thus there is an urgent unmet need for improved treatment strategies for ovarian cancer.

This report summarizes the perspectives of 7 highly regarded ovarian cancer specialists (all US-based). In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics. The next big thing will be Avastin, so the Panel evaluates inhibitors of PARP and mTOR/PI3K/AKT (& MEK) in a world where oncologists have moved from platinum doublets to a triplet containing bevacizumab, carboplatin and (paclitaxel / gemcitabine / doxorubicin). The Panel identifies strengths and weaknesses for lead compounds amongst the most important mechanisms in development for ovarian cancer.

Key Topics Covered:

• Top-Ten Report Highlights
• Ovarian Cancer Standards of Care / Unmet Needs
• Subtypes of Ovarian Cancer and Clinical Trial Recommendations
• Genomics / Biomarkers
• Pharmacotherapies (Alphabetical by Target)
• Angiogenesis inhibitors (VEGF / PDGF /FGF / VDA)
• Avastin; bevacizumab (Genentech)
• aflibercept; VEGF Trap (Sanofi-Aventis),
• Nexavar; sorafenib (Bayer-Schering/Onyx), Sutent; sunitinib (Pfizer)
• Recentin; cediranib (AstraZeneca)
• brivanib (Bristol-Myers Squibb)
• Votrient; pazopanib (GlaxoSmithKline)
• BIBF-1120 (Boehringer Ingelheim)
• fosbretabulin; CA4P (OxiGene)
• ASA404 (Novartis)
• Tarceva; erlotinib (OSI Pharmaceuticals / Genentech)
• a-folate receptor inhibitors
• Farletuzumab (Morphotek /Eisai)
• EC-145 (Endocyte)
• Hedgehog Pathway Inhibitors
• perifosine; KRX-0401 (Keryx)
• Torisel; temsirolimus (Pfizer)
• Afinitor; everolimus (Novartis)
• olaparib; AZD2281 (AstraZeneca)
• BSI201 (BiPar Sciences / Sanofi-Aventis)
• Taxol; paclitaxel (Bristol-Myers Squibb)
• Abraxane (Abraxis)
• Xyotax; a.k.a. Opaxio (Cell Therapeutics)
• patupilone (Novartis)
• Thought Leader Interviews

For more information visit http://www.researchandmarkets.com/research/58e432/thought_leader_ins

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716